NOD1 antagonist-2
NOD1 antagonist-2 (compound 66) is an orally active selective antagonist of both human and mouse NOD1. NOD1 antagonist-2 (compound 66) antagonizes NOD1-induced NF-κB and MAPK pathways.
For research use only. We do not sell to patients.
- CAS No.: 3099180-63-6
- Formula: C21H13Cl2F2N3O5S2
- Molecular Weight:560.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
hNOD1 0.8 nM (IC50, in HEK293 cells) |
mNOD1 32 nM (IC50, in HEK293 cells) |
In Vitro
NOD1 antagonist-2 (compound 66) demonstrates promising antagonistic activity against both h/mNOD1-induced NF-κB activation in HEK293 cells (IC50 = 0.8 nM and 32 nM, respectively)[1].
NOD1 antagonist-2 (compound 66, 0.1, 1 μM) markedly inhibits the increases in p-RIP2, p-p65, p-p38, and p-JNK of both THP-1 cells and mBMDMs, demonstrating its efficacy in modulating NOD1-induced signaling pathways[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 3099180-63-6
-
Molecular Weight 560.38
-
Formula C21H13Cl2F2N3O5S2
-
SMILES
CS(C1=CC=C(N=C(Cl)N(C2=CC(NS(=O)(C3=C(F)C=CC=C3F)=O)=C(Cl)C=C2)C4=O)C4=C1)(=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NOD1 antagonist-2 Related Classifications
HY-170447 Related Classifications
Powered by Bioz